Total Funding
14
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
987337
InoCardia has developed the ‘work-loop’ model as a pre-clinical myocardial assay assessing cardiac contractility.
- Jeremy Billson: CEO
- Helen Maddock: Founder and Chief Scientific OfficerPast Role: University College London (UCL), BHF Research Fellow
About the Company
Inocardia is a Coventry University spinout focused on the provision of Contract Research Services via the development of assays targeted at the biotech and pharmaceutical sectors. Inocardia has developed the ‘work-loop’ model as a pre-clinical myocardial assay assessing cardiac contractility in normal, diseased and ageing myocardium in order to
determine the cardiovascular safety of lead pharmaceutical compounds. The Coventry University work-loop assay is the only relevant in-vitro human model of cardio-toxicity available worldwide. Both the pharmaceutical industry and regulators recognise that contractility assessment is currently fraught with problems.
